SNGLR Capital
SNGLR Capital, founded in 2021 and based in Zug, Switzerland, is a venture capital firm that focuses on early-stage technology startups with high growth potential. The firm primarily invests in European companies in sectors such as artificial intelligence, blockchain, data (including Internet of Things and APIs), 5G, and robotics. SNGLR Capital aims to support entrepreneurs throughout their journey by leveraging the experience of its team, which includes founders, early-stage investors, board members, advisors, and mentors. The firm also collaborates with selected corporate venture units and consulting firms to enhance market access, while providing technology insights and support through its specialized development programs.
Cellestia Biotech AG, a biopharmaceutical company, engages in the development of anti-cancer drugs that modulate the NOTCH signaling pathway for the treatment of oncology and immunological disorders. The company focuses on developing its lead development candidate CB-103, which is a small molecule drug candidate. Its CB-103 is a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The company also focuses on developing NOTCH-specific PD biomarkers and diagnostics for patient selection. Cellestia Biotech AG was founded in 2014 and is headquartered in Basel, Switzerland with an additional location in Lausanne.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.